PODD
HealthcareInsulet Corporation · Medical - Devices · $11B
What is Insulet Corporation?
Insulet Corporation makes insulin delivery systems designed to simplify life for people with insulin-dependent diabetes. Its flagship Omnipod platform has built a loyal global user base across North America, Europe, and beyond.
Insulet generates revenue by selling its tubeless Omnipod insulin delivery devices and related consumables through pharmacy channels, independent distributors, and direct sales. The disposable pod design creates a recurring purchase cycle, supporting predictable demand. Products reach customers across the United States, Canada, Europe, the Middle East, and Australia.
Incorporated in 2000 and headquartered in Acton, Massachusetts.
- Omnipod tubeless insulin delivery system
- Disposable self-adhesive pod worn up to three days
- Wireless handheld personal diabetes manager
- Pharmacy and direct distribution channels
Is PODD a Good Stock to Buy?
UQS Score rates PODD as Good overall.
Growth stands out as the strongest pillar, reflecting Insulet's expanding global footprint in diabetes care. The Risk pillar also rates Good, suggesting the business carries a manageable risk profile relative to sector peers.
Moat and Valuation both rate Neutral, indicating the competitive advantage is not yet considered wide, and the current price does not offer an obvious discount.
See the exact pillar breakdown and full financial metrics by signing up for a Pro account on UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does PODD pay dividends?
No — Insulet Corporation does not currently pay a dividend.
Insulet does not currently pay a dividend. As a growth-oriented medical device company, it reinvests available capital into product development, geographic expansion, and manufacturing scale rather than returning cash to shareholders through distributions.
When does PODD report earnings?
Insulet Corporation reports earnings on a quarterly cadence, typical for US-listed equities.
Quarterly results have generally reflected continued expansion in international markets and growing adoption of the Omnipod platform. Revenue trends have been supported by the recurring consumable nature of the pod business.
For the most recent quarter's results, visit Insulet Corporation's investor relations page directly.
PODD Price History
-28.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Insulet Corporation?
Based on Insulet Corporation's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Insulet Corporation do?
Insulet develops and sells the Omnipod insulin delivery system, a tubeless, self-adhesive pod worn on the body for up to three days. It serves people with insulin-dependent diabetes through pharmacy and distributor channels in the US, Canada, Europe, the Middle East, and Australia.
Does PODD pay dividends?
No, PODD does not pay a dividend. Insulet reinvests its capital into growth initiatives, including international expansion and product innovation, rather than distributing cash to shareholders.
When does PODD report earnings?
Insulet reports on a standard quarterly schedule. For exact dates and the most recent results, check the investor relations section of Insulet's official website.
Is PODD a good stock to buy?
UQS Score rates PODD as Good, with a particularly Strong Growth pillar. Moat and Valuation are both Neutral, meaning competitive positioning and pricing merit attention. The full pillar breakdown is available to Pro members on UQS Score.
Is PODD overvalued?
PODD's Valuation pillar rates Neutral under the UQS framework, suggesting the stock is neither clearly cheap nor obviously expensive relative to its fundamentals. Pro members can view the detailed valuation metrics behind this assessment.
What is PODD's market cap bracket?
Insulet Corporation is classified as a large-cap company, placing it among the more established players in the medical device space.
Who founded Insulet Corporation?
Insulet was founded by John Brooks, who developed the concept for a tubeless insulin delivery device. The company was incorporated in 2000 and is now headquartered in Acton, Massachusetts.
Is PODD a long-term quality indicator?
The UQS framework rates PODD Good overall, with a Strong Growth pillar and Good Risk profile — both relevant to long-term quality assessment. Moat rates Neutral, which is a factor worth monitoring for investors focused on durable competitive advantage.
Unlock Full PODD Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar scores
- ✓Access detailed financial metrics behind each pillar
- ✓Compare PODD against sector peers side by side
- ✓Get the complete analyst-style quality breakdown
Pro Analysis
PODD — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 65.5 | 68.3 | 55.0 | 82.1 | 64.7 | 57.0 | +0.1 |
| May 21, 2026 | 65.4 | 68.2 | 55.0 | 82.1 | 64.7 | 56.4 | -0.8 |
| May 17, 2026 | 66.2 | 68.7 | 55.0 | 82.1 | 64.7 | 60.8 | +0.2 |
| May 16, 2026 | 66.0 | 68.7 | 55.0 | 82.1 | 64.7 | 59.9 | +0.1 |
| May 13, 2026 | 65.9 | 68.6 | 55.0 | 82.1 | 64.7 | 59.3 | +0.4 |
| May 12, 2026 | 65.5 | 68.3 | 55.0 | 82.1 | 64.7 | 56.8 | +1.3 |
| May 7, 2026 | 64.2 | 60.1 | 55.0 | 82.1 | 69.4 | 57.3 | +0.6 |
| May 3, 2026 | 63.6 | 60.1 | 55.0 | 82.1 | 69.4 | 53.0 | +0.4 |
| Apr 26, 2026 | 63.2 | 60.1 | 55.0 | 82.1 | 69.4 | 50.6 | +0.4 |
| Apr 19, 2026 | 62.8 | 60.1 | 55.0 | 82.1 | 69.4 | 48.1 | -0.2 |
PODD — Pillar Breakdown
Quality
— 68.3/100 (25%)Insulet Corporation shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 82.1/100 (20%)Insulet Corporation is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 64.7/100 (15%)Insulet Corporation maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 57.1/100 (15%)Insulet Corporation trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 55/100 (25%)Insulet Corporation has meaningful competitive advantages that should protect its market position. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for PODD.
Score Composition
Financial Data
More Stock Analysis
How is the PODD UQS Score Calculated?
The UQS (Unified Quality Score) for Insulet Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Insulet Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Insulet Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.